Skip to main content
. 2015 Nov 4;14:437. doi: 10.1186/s12936-015-0969-8

Fig. 6.

Fig. 6

Predicted and observed efficacy against clinical disease by three-monthly periods by trial site for the 6–12 weeks cohort with booster using best-fitted vaccine profile. Reported efficacy (mean and 95 % CI) in the trial site is indicated by black circles. Prediction estimates in purple (median and 95 % CI)